Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Hoffmann-La Roche
Non-Small Cell Lung Cancer
1 trial -
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Hoffmann-La Roche
Renal Cell Carcinoma
1 trial -
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
1 trial -
Atogepant
AbbVie Deutschland GmbH & Co. KG
Chronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)
1 trial -
Atogepant, Placebo for Atogepant
AbbVie Deutschland GmbH & Co. KG
Chronic Migraine
1 trial -
Atogepant, Placebo for Atogepant
AbbVie Deutschland GmbH & Co. KG
Menstrual Migraine
1 trial -
Atogepant, Placebo for atogepant tablets 60mg
AbbVie Deutschland GmbH & Co. KG
Migraine
1 trial -
Atomoxetine Aurobindo 40 mg hard capsules, Microcrystalline cellulose gelatin capsule
Disc Medicine
Parkinson's disease
1 trial -
Atropine Eye Drops, Solution (0.05% w/v), Atropine Eye Drops, Solution (0.025% w/v), The placebo consists of the same composition as the atropine eye drops except for the active substance.
Elan Pharma International
Myopia
1 trial -
Attentin 10 mg Tablette, Dexamfetamine sulfate 20 mg modified-release capsule, Placebo for Test 1 - 5 mg, Attentin 5 mg, Tablette, Placebo for test 2 - 10 mg, Placebo for test 1 - 10 mg, Placebo for test 2 - 20 mg, Dexamfetamine sulfate 15 mg modified-release capsule, Placebo for test 2 - 15 mg, Dexamfetamine sulfate 10 mg modified-release capsule
Medice Arzneimittel PΓΌtter GmbH & Co. KG
Patients with ADHD (according to ICD-10 / DSM-5)
1 trial -
Atumelnant
Crinetics Pharmaceuticals Europe GmbH
Congenital Adrenal Hyperplasia
2 trials -
Atumelnant 120 mg tablets, Atumelnant 80 mg tablets, Tablet
Lacuna Pharma Pty Ltd
Classic Congenital Adrenal Hyperplasia
1 trial -
Atumelnant 80 mg tablets, Atumelnant 40 mg tablet, Atumelnant 20 mg tablets, Tablet
Lacuna Pharma Pty Ltd
Classic congenital adrenal hyperplasia
1 trial -
Augmentin Fruit, 400 mg/57 mg/5 ml suukaudse suspensiooni pulber
Istituto Gentili S.r.l.
Urinary Tract Infections
1 trial -
Autologous Peripheral Blood Stem Cell injection
Hospital Authority, Hong Kong
Acute Myocardial Infarction
1 trial -
Avacincaptad pegol, FLUORESCEIN
Astellas Pharma GmbH
geographic atrophy
1 trial -
Avastin 25 mg/ml concentrate for solution for infusion., Lonsurf 20 mg/8.19 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, Xeloda 150 mg film-coated tablets, Xeloda 500 mg film-coated tablets, Avastin 25 mg/ml concentrate for solution for infusion.
The George Institute
Metastatic colorectal cancer
1 trial -
Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM LEVOFOLINATE , MK-1084, CETUXIMAB , MVASI 25 mg/mL concentrate for solution for infusion, FLUOROURACIL , Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM FOLINATE , OXALIPLATIN , MK-1084, MVASI 25 mg/mL concentrate for solution for infusion
Merck Sharp and Dohme
KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer
1 trial -
Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion
The George Institute
intermediate-stage hepatocellular carcinoma
1 trial -
Avelumab
Pfizer
Advanced Malignancies
1 trial -
Avelumab
Serono Europe Limited
First Line Non-Small Cell Lung Cancer
1 trial -
Avexitide
Amylyx Pharmaceuticals EMEA B.V.
Post Bariatric Hypoglycemia
1 trial -
Avtozma 20 mg/mL concentrate for solution for infusion., BI 764532, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer InfusionslΓΆsung, Etoposid Hikma 20 mg/ml Konzentrat zur Herstellung einer InfusionslΓΆsung
Boehringer Ingelheim
advanced or metastatic extrapulmonary neuroendocrine carcinoma
1 trial -
Axatilimab (INCA034176)
Incyte
Chronic Graft-Versus-Host Disease
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources